Compare Levi Strauss & Co. (LEVI) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Tilray Brands Inc — how do they compare? Levi Strauss & Co. trades at $18.69 (market cap $7.31B), while Tilray Brands Inc trades at $3.51 (market cap $530.54M). The key difference: Levi Strauss & Co. is far larger — about 13.8× Tilray Brands Inc's market cap, and Levi Strauss & Co. pays a 3.36% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Tilray Brands Inc for 31 Days on average.
| LEVI | TLRY | |
|---|---|---|
Market Cap | $7.31B | $530.54M |
Volume | 13,683,095 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $21.00 |
52-Week Low | $17.92 | $3.57 |
Typical Hold Time | 70 Days | 31 Days |
Enterprise Value | $8.86B | $684.46M |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.71, down 4.13% today, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, maintains a healthy gross margin of 62.81%, and shows improving cash flow trends. Analyst consensus remains strongly bullish with a $29.00 price target, representing 55% upside potential from current levels.
The stock presents a compelling value opportunity with a P/E of 12.5x and strong brand momentum, though technical weakness and recent cybersecurity incidents pose near-term risks. Wall Street's overwhelming buy rating (79%) suggests confidence in Levi's direct-to-consumer strategy and international expansion driving future growth.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
